Literature DB >> 32736208

Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.

Nikolina Kesar1, Ria Winkelmann2, Julius Oppermann1, Shahram Ghanaati3, Daniel Martin1, Thomas Neumayer4, Sven Balster4, Claus Rödel5, Franz Rödel5, Jens von der Grün1, Panagiotis Balermpas6.   

Abstract

OBJECTIVES: Aim of the study was to evaluate the prognostic impact of CD8-positive (CD8+) tumour-infiltrating lymphocytes (TILs) and PD-L1 expression on the outcome of patients with malignant salivary gland neoplasms.
MATERIALS AND METHODS: Formalin-fixed, paraffin-embedded tissue samples and clinicopathological data from patients treated for salivary gland carcinoma in a head and neck cancer centre were retrospectively retrieved. Immunohistochemical staining was applied on sections of 84 specimens of 12 different histological subtypes. Both CD8 and PD-L1 expression were rated by semi-automated cell counts by a digital image analysis programme. Survival analyses were performed by the log-rank test on the univariate level, and the Cox model was applied on the multivariate level. Associations between immunological markers and clinicopathological variables were estimated by the Pearson chi-squared test. Additionally, PD-1 was estimated as an exhaustion marker of CD8+ TILs.
RESULTS: Patients exceeding a tumour proportion score ≥5% regarding PD-L1 expression demonstrated a significantly decreased survival, as did individuals with an overall high CD8+ cell density. Particularly, high CD8+ cell counts in the invasive front of the respective tumour tissue significantly coincided with a poor outcome. Also, high numbers of CD8+ TILs significantly matched with a high quantity of PD-1+ TILs.
CONCLUSION: CD8+ TILs abundance in the peritumoural microenvironment correlates with impaired outcome of patients with salivary gland carcinoma. The simultaneous negative prognostic impact of PD-L1 expression and presence of PD-1+ TILs advocates an immune checkpoint-controlled mechanism of CD8+ TILs exhaustion for these tumours and paves the way for future treatment strategies.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD8; Exhaustion; Head and neck cancer; Immunohistochemistry; PD-1; PD-L1; Salivary gland cancer; Survival; Tumour-infiltrating lymphocytes

Year:  2020        PMID: 32736208     DOI: 10.1016/j.oraloncology.2020.104931

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  6 in total

1.  Mutually Exclusive Expression of COL11A1 by CAFs and Tumour Cells in a Large panCancer and a Salivary Gland Carcinoma Cohort.

Authors:  Alexander Quaas; Jens Peter Klußmann; Christoph Arolt; Franziska Hoffmann; Lisa Nachtsheim; Philipp Wolber; Orlando Guntinas-Lichius; Reinhard Buettner; Ferdinand von Eggeling
Journal:  Head Neck Pathol       Date:  2021-08-10

2.  TGFβ1: An Indicator for Tumor Immune Microenvironment of Colon Cancer From a Comprehensive Analysis of TCGA.

Authors:  Jinyan Wang; Jinqiu Wang; Quan Gu; Yan Yang; Yajun Ma; Quan'an Zhang
Journal:  Front Genet       Date:  2021-04-28       Impact factor: 4.599

3.  PD-L1 expression and immune cells infiltration in primary tracheobronchial neoplasm.

Authors:  Kai-Fu Zheng; Yu-Jian Liu; Nan Ma; Li Gong; Xiao-Fei Li; Jin-Bo Zhao; Yan-Lu Xiong; Xi-Yang Tang; Qian Zhang; Zhong-Lin Luo; Huan-Huan Tian; Paul Hofman; Yoshinobu Ichiki; Giulio Metro; Motoko Tachihara
Journal:  Transl Lung Cancer Res       Date:  2021-12

4.  Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma.

Authors:  Qigen Fang; Yao Wu; Wei Du; Xu Zhang; Defeng Chen
Journal:  Front Oncol       Date:  2021-08-26       Impact factor: 6.244

5.  Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis.

Authors:  Limeng Wu; Canhua Jiang; Zhihui Zhu; Yao Sun; Tao Zhang
Journal:  PLoS One       Date:  2022-07-26       Impact factor: 3.752

Review 6.  Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.

Authors:  Siqing Jiang; Xin Li; Lihua Huang; Zhensheng Xu; Jinguan Lin
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.